Full-year 2026 revenue guidance raised
Company: CoreWeave
The claim, verbatim
CoreWeave raised full-year 2026 revenue guidance to between $12.4 billion and $13.2 billion
Source (primary)
‘Pharma Bro’ Martin Shkreli ‘Covered’ CoreWeave Short Position: CRWV Stock Slides For Third Session - TradingView (-, news_article)
View cached copy (2026-09-01)Live source ↗
Quote: “Subsequently, CoreWeave raised its full-year 2026 guidance. The company expects revenue between $12.4 billion and $13.2 billion, up from its May projection of $12 billion to $13 billion.”
How we checked this
Checked on September 19, 2026. The cited source supports every part of this claim.
The document explicitly states CoreWeave raised full-year 2026 guidance to revenue of $12.4 billion to $13.2 billion.
Confirmed in the source:
- CoreWeave raised its full-year 2026 revenue guidance to between $12.4 billion and $13.2 billion
What we did: Read our cached copy of the publisher (https://www.tradingview.com/news/stocktwits:3ac1780d8094b:0-pharma-bro-martin-shkreli-covered-coreweave-short-position-crwv-stock-slides-for-third-session/) in full (5,190 characters, retrieved September 1, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms ‘Pharma Bro’ Martin Shkreli ‘Covered’ CoreWeave Short Position: CRWV Stock Slides For Third Session - TradingView
Quote: “Subsequently, CoreWeave raised its full-year 2026 guidance. The company expects revenue between $12.4 billion and $13.2 billion, up from its May projection of $12 billion to $13 billion.”